Information Provided By:
Fly News Breaks for March 2, 2020
BEAM
Mar 2, 2020 | 08:30 EDT
As previously reported, Wedbush analyst David Nierengarten initiated coverage of Beam Therapeutics with an Outperform rating and $32 price target. The analyst believes shares are "undervalued" based on his positive long-term outlook on the company's differentiated and potentially best-in-class gene editing platform, base editing, which is able to generate highly efficient and predictable single base pair changes in genomic DNA in order to correct genetic disease.
News For BEAM From the Last 2 Days
BEAM
Mar 26, 2024 | 06:37 EDT
Beam Therapeutics announced the clearance of its clinical trial authorisation - CTA - application by the U.K. Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1 antitrypsin deficiency, or AATD. AATD is an inherited genetic condition that can cause serious lung and liver disease, which can lead to significant debility and reduced life expectancy for patients. Preclinical data demonstrated the ability of BEAM-302 to significantly increase levels of corrected and functional alpha-1 antitrypsin and reduce the mutant PiZ AAT protein in in vivo rodent disease models at clinically relevant doses. The Phase 1/2 clinical trial is a study that will evaluate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 initially in patients with AATD-associated lung disease. The study design includes a dose exploration portion followed by a dose expansion portion to identify the optimal dose to take forward in a pivotal study. The company expects to initiate the Phase 1/2 trial of BEAM-302 in the UK in the first half of 2024.